Novartis data at EADV show consistent efficacy of AIN457 (secukinumab) in clearing skin of psoriasis patients

Novartis announced that new analyses of AIN457 (secukinumab) Phase III studies showed that treatment with secukinumab 300 mg resulted in higher rates of clear to almost clear skin at Week 12 versus placebo, regardless of patients' psoriasis disease severity (p<0.0001)[1].